{"id":"https://openalex.org/W2016709233","doi":"https://doi.org/10.1097/00004850-200411000-00007","title":"Aripiprazole and neuroleptic malignant syndrome","display_name":"Aripiprazole and neuroleptic malignant syndrome","publication_year":2004,"publication_date":"2004-10-14","ids":{"openalex":"https://openalex.org/W2016709233","doi":"https://doi.org/10.1097/00004850-200411000-00007","mag":"2016709233","pmid":"https://pubmed.ncbi.nlm.nih.gov/15486522"},"language":"en","primary_location":{"id":"doi:10.1097/00004850-200411000-00007","doi":"https://doi.org/10.1097/00004850-200411000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200411000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034541609","display_name":"Nandini Chakraborty","orcid":"https://orcid.org/0000-0003-4709-9573","observed_orcids":["https://orcid.org/0000-0003-4709-9573"]},"institutions":[{"id":"https://openalex.org/I2799497666","display_name":"NHS Ayrshire and Arran","ror":"https://ror.org/03kq24308","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799497666"]},{"id":"https://openalex.org/I2800480304","display_name":"University Hospital Ayr","ror":"https://ror.org/01dsy9055","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799497666","https://openalex.org/I2800480304"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Nandini Chakraborty","raw_affiliation_strings":["Department of Psychiatry, Ailsa Hospital, Ayr, UK. nandini_dass@rediffmail.com","Conflict of interest: Dr Johnston has previously received educational sponsorship from numerous companies who market atypical antipsychotic drugs that are licensed in the UK. This includes a sponsorship from Otsuka/Bristol Myers Squib (the company that markets Aripiprazole) to attend a European Conference in 2003","Department of Psychiatry, Ailsa Hospital, Ayr, UK","requests for reprints to Dr Nandini Chakraborty, Ailsa Hospital, Dalmellington Road, Ayr KA6 6AB, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, Ailsa Hospital, Ayr, UK. nandini_dass@rediffmail.com","institution_ids":["https://openalex.org/I2799497666"]},{"raw_affiliation_string":"Conflict of interest: Dr Johnston has previously received educational sponsorship from numerous companies who market atypical antipsychotic drugs that are licensed in the UK. This includes a sponsorship from Otsuka/Bristol Myers Squib (the company that markets Aripiprazole) to attend a European Conference in 2003","institution_ids":[]},{"raw_affiliation_string":"Department of Psychiatry, Ailsa Hospital, Ayr, UK","institution_ids":["https://openalex.org/I2799497666","https://openalex.org/I2800480304"]},{"raw_affiliation_string":"requests for reprints to Dr Nandini Chakraborty, Ailsa Hospital, Dalmellington Road, Ayr KA6 6AB, UK","institution_ids":["https://openalex.org/I2799497666"]}]},{"author_position":"last","author":{"id":null,"display_name":"Timothy Johnston","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799497666","display_name":"NHS Ayrshire and Arran","ror":"https://ror.org/03kq24308","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799497666"]},{"id":"https://openalex.org/I2800480304","display_name":"University Hospital Ayr","ror":"https://ror.org/01dsy9055","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799497666","https://openalex.org/I2800480304"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Timothy Johnston","raw_affiliation_strings":["Conflict of interest: Dr Johnston has previously received educational sponsorship from numerous companies who market atypical antipsychotic drugs that are licensed in the UK. This includes a sponsorship from Otsuka/Bristol Myers Squib (the company that markets Aripiprazole) to attend a European Conference in 2003","Department of Psychiatry, Ailsa Hospital, Ayr, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Conflict of interest: Dr Johnston has previously received educational sponsorship from numerous companies who market atypical antipsychotic drugs that are licensed in the UK. This includes a sponsorship from Otsuka/Bristol Myers Squib (the company that markets Aripiprazole) to attend a European Conference in 2003","institution_ids":[]},{"raw_affiliation_string":"Department of Psychiatry, Ailsa Hospital, Ayr, UK","institution_ids":["https://openalex.org/I2799497666","https://openalex.org/I2800480304"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034541609"],"corresponding_institution_ids":["https://openalex.org/I2799497666","https://openalex.org/I2800480304"],"apc_list":null,"apc_paid":null,"fwci":5.4038,"has_fulltext":false,"cited_by_count":63,"citation_normalized_percentile":{"value":0.95548761,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"19","issue":"6","first_page":"351","last_page":"353"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.9887999892234802,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.011099999770522118,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12666","display_name":"Historical Psychiatry and Medical Practices","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":1.0},{"id":"https://openalex.org/keywords/neuroleptic-malignant-syndrome","display_name":"neuroleptic malignant syndrome","score":0.9990000128746033},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8960000276565552},{"id":"https://openalex.org/keywords/treatment-resistant-schizophrenia","display_name":"treatment-resistant schizophrenia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.902999997138977},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5619999766349792}],"concepts":[{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.9924257397651672},{"id":"https://openalex.org/C2777964233","wikidata":"https://www.wikidata.org/wiki/Q1424956","display_name":"Neuroleptic malignant syndrome","level":2,"score":0.8987144827842712},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6306711435317993},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5668824911117554},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5504601001739502},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.5394483804702759},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5231605768203735},{"id":"https://openalex.org/C3019878999","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic drug","level":4,"score":0.4475744366645813},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.393765389919281},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.23184803128242493}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009459","descriptor_name":"Neuroleptic Malignant Syndrome","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009459","descriptor_name":"Neuroleptic Malignant Syndrome","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009459","descriptor_name":"Neuroleptic Malignant Syndrome","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004850-200411000-00007","doi":"https://doi.org/10.1097/00004850-200411000-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004850-200411000-00007","pdf_url":null,"source":{"id":"https://openalex.org/S149156103","display_name":"International Clinical Psychopharmacology","issn_l":"0268-1315","issn":["0268-1315","1473-5857"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:15486522","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15486522","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International clinical psychopharmacology","raw_type":"Case Reports"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8700000047683716,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W2007726170","https://openalex.org/W2008122290","https://openalex.org/W2010741426","https://openalex.org/W2011053359","https://openalex.org/W2017118824","https://openalex.org/W2055595962","https://openalex.org/W2082000302","https://openalex.org/W2114801996","https://openalex.org/W2142436561"],"related_works":["https://openalex.org/W2758948115","https://openalex.org/W2016709233","https://openalex.org/W2133014932","https://openalex.org/W3210733378","https://openalex.org/W2542773835","https://openalex.org/W4231323125","https://openalex.org/W2939947704","https://openalex.org/W2333485214","https://openalex.org/W3034401693","https://openalex.org/W2169353848"],"abstract_inverted_index":{"Aripiprazole,":[0],"an":[1,71],"atypical":[2,78],"antipsychotic":[3],"with":[4,39,63,76],"a":[5,15,56,82],"novel":[6],"method":[7],"of":[8],"action,":[9],"has":[10],"only":[11],"recently":[12],"been":[13],"awarded":[14],"license":[16],"in":[17,55,96],"the":[18,46,90,97],"UK.":[19],"We":[20],"report":[21,50],"our":[22,42],"first":[23,47],"patient":[24],"to":[25,99],"receive":[26],"this":[27,44,64,69],"drug,":[28],"who":[29],"had":[30],"treatment-resistant":[31],"schizophrenia":[32],"and":[33,53],"developed":[34],"neuroleptic":[35],"malignant":[36],"syndrome":[37],"(NMS)":[38],"aripiprazole.":[40],"To":[41],"knowledge,":[43],"is":[45,70],"published":[48],"case":[49,73],"involving":[51],"aripiprazole":[52],"NMS":[54],"potentially":[57],"fatal":[58],"medical":[59],"emergency.":[60],"Further":[61],"experience":[62],"drug":[65],"should":[66],"indicate":[67],"whether":[68],"isolated":[72],"(as":[74],"described":[75,95],"other":[77],"antipsychotics)":[79],"or":[80],"constitutes":[81],"more":[83],"serious":[84],"risk":[85],"than":[86],"that":[87],"suggested":[88],"by":[89],"relatively":[91],"beneficial":[92],"therapeutic":[93],"profile":[94],"literature":[98],"date.":[100]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-10T00:00:00"}